New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
14:41 EDTILMN, LMNX, DGX, LH, PACB, VCYT, SQNM, QGEN, MYGN, GHDXFDA draft lab tests guidelines not as bad as feared, says Piper Jaffray
After the FDA announced it intends to issue draft guidance on regulations for lab developed tests, Piper Jaffray said the proposed guidelines appear "less onerous" than the firm initially expected. Piper added that the FDA intends to leverage existing studies in lieu of requiring additional studies, which the firm views as positive for companies with well validated offerings such as Genomic Health (GHDX), Myriad Genetics (MYGN), QIAGEN (QGEN), Sequenom (SQNM), and Veracyte (VCYT).
News For GHDX;MYGN;QGEN;SQNM;VCYT;DGX;ILMN;LH;LMNX;PACB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 22, 2015
12:10 EDTDGX, LHQuest declines comment to Bloomberg on takeover speculation
Quest Diagnostics (DGX) declined comment to Bloomberg regarding the takeover speculation that pushed the company's stock higher today. Shares of Quest are up $7.01 to $80.89 in midday trading. Shares spiked earlier in the trading day amid talk among traders that Quest hired an investment bank to explore a sale after being approached by a suitor. The talk is unconfirmed speculation that has not been reported by any news agencies. Quest peer LabCorp (LH) is up $1.74 to $122.10 at midday.
10:46 EDTLHLabCorp volatility increases
Subscribe for More Information
10:43 EDTLH, DGXQuest Diagnostics jumps amid takeover speculation
The move higher in Quest Diagnostics (DGX), which was earlier halted for volatility and remains up 15% to $85 per share in morning trading, has been attributed to takeover speculation. Peer Lab Corp. (LH) is also up 3.9% to $125 in morning trading.
10:35 EDTSQNMSequenom genetic test false positive highlighted in NBC Nightly News report
Recent studies have "cast doubt" on the reliability of pre-natal genetic tests such as Sequenom's MaterniT21 test, according to a report aired by NBC Nightly News. Reference Link
10:19 EDTDGXQuest Diagnostics calls active on renewed takeover chatter
Quest Diagnostics June 75 and 80 calls are active on total call volume of 2,100 contracts (100 puts) on renewed takeover chatter. June call option implied volatility is at 18, July is at 19; compared to its 26-week average of 19. Active call volume suggests traders taking positions for upside price movement.
10:15 EDTDGXRumor: Quest Diagnostics moves up on renewed takeover chatter
Subscribe for More Information
May 21, 2015
16:54 EDTVCYTVeracyte files to sell 4.9M shares of common stock for holders
Subscribe for More Information
08:16 EDTGHDXGenomic Health's Oncotype prostate cancer test issued draft LCD determination
Subscribe for More Information
May 20, 2015
15:32 EDTVCYTVeracyte reports positive data on company's molecular classifier
Subscribe for More Information
08:08 EDTGHDXGenomic Health's Oncotype prostate cancer risk test shows positive results
Subscribe for More Information
May 19, 2015
09:31 EDTLHORIG3N announces strategic collaboration with LabCorp
Subscribe for More Information
09:18 EDTQGEN, ILMNBofA/Merrill life sciences analysts hold an analyst/industry conference call
Analysts, along with Nancy J. Kelley, a nationally recognized executive and lawyer who has championed the field of Synthetic/Engineering Biology in the U.S., discuss what Synthetic Biology is and whether it will disrupt the Healthcare landscape and how Synthetic Biologic-based products would be regulated on an Analyst/Industry conference call to be held on May 19 at 2 pm.
07:28 EDTLHUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
May 18, 2015
16:07 EDTILMNIllumina files new patent infringement suit against Roche unit
Subscribe for More Information
10:18 EDTVCYTVeracyte has Percepta market opportunity above $175M, says Piper Jaffray
Following the publication of results from studies that assessed the performance of Veracyte's Percepta test in lung cancer diagnosis, Piper Jaffray said the data was in line with previous diligence and that it expects the NEJM publication to help drive adoption. The firm, which estimates the initial domestic market opportunity for the test at $177M-$236M, kept its Overweight rating and $13 price target on Veracyte shares.
08:46 EDTLHLabCorp announces full portfolio of Hep C virus drug resistance assays
LabCorp announced the launch of two new Hepatitis C Virus drug resistance assays. The HCV NS5A and NS5B Drug Resistance Assays expand LabCorp’s portfolio of HCV resistance tests that includes HCV GenoSure NS3/4A, which was launched in 2011. These tests are available through Monogram Biosciences, a member of the LabCorp Specialty Testing Group, and a leader in the development and commercialization of innovative antiviral diagnostics.
08:05 EDTGHDXGenomic Health announces results from study on methods to detect bladder cancer
Genomic Health announced positive results from a second, larger liquid biopsy feasibility study demonstrating the Company's ability to detect tumor-specific DNA in urine, which is expected to enable bladder cancer recurrence monitoring. It is estimated that early-stage bladder cancer recurs in only 10 to 15 percent of patients in the first year, and in more than half of patients over time. However, approximately one-third of all cystoscopies – a procedure using a thin instrument equipped with a camera and light to look at the inside of the bladder – generate false positive results. Genomic Health and its collaborators used the Company's next-generation sequencing and polymerase chain reaction based platforms and refined methodology to target tumor-specific differential DNA methylation and single nucleotide variations. In the study, researchers identified tumor-specific DNA markers in 94 percent of tissue samples and found a strong association between the same markers in urine. These findings are expected to enable accurate monitoring for cancer recurrence in the urine of early-stage bladder cancer patients.
07:10 EDTVCYTVeracyte announces publication of results from two Percepta trials
Veracyte announced online publication in the New England Journal of Medicine of results from two large, prospective, multicenter studies that assessed the clinical performance of the company's Percepta Bronchial Genomic Classifier in lung cancer diagnosis. Findings from the AEGIS I and AEGIS II trials demonstrate the ability of the genomic test to help patients safely avoid unnecessary invasive, risky procedures on suspicious lung nodules or lesions that were initially found on computed tomography, or CT, scans. The AEGIS trials involved 639 patients at 28 sites in the United States, Canada and Ireland who were undergoing bronchoscopy, a common nonsurgical procedure, to assess lung nodules for cancer. Specifically, among patients assessed clinically as having "intermediate" risk of malignancy who then had a non-diagnostic bronchoscopy, the Percepta test had a negative predictive value, or NPV, of 91%, demonstrating the test's ability to reclassify these patients as "low risk" with a high degree of accuracy. The genomic test and the bronchoscopy had a combined sensitivity of 97%, compared to 75% for bronchoscopy alone. The genomic test's specificity was 47% in both studies. The sensitivity of the Percepta classifier alone and in combination with bronchoscopy was consistently high, regardless of nodule size and location, and cancer stage and type.
07:04 EDTVCYTVeracyte announces publication of results from two studies of Percepta
Subscribe for More Information
05:03 EDTVCYTVeracyte Percepta study published in New England Journal of Medicine
Veracyte announced online publication in the New England Journal of Medicine of results from two large, prospective, multicenter studies that assessed the clinical performance of the company's Percepta Bronchial Genomic Classifier in lung cancer diagnosis. Findings from the AEGIS I and AEGIS II trials demonstrate the ability of the genomic test to help patients safely avoid unnecessary invasive, risky procedures on suspicious lung nodules or lesions that were initially found on computed tomography, or CT, scans. The AEGIS trials involved 639 patients at 28 sites in the United States, Canada and Ireland who were undergoing bronchoscopy, a common nonsurgical procedure, to assess lung nodules for cancer. Specifically, among patients assessed clinically as having "intermediate" risk of malignancy who then had a non-diagnostic bronchoscopy, the Percepta test had a negative predictive value, or NPV, of 91%, demonstrating the test's ability to reclassify these patients as "low risk" with a high degree of accuracy. The genomic test and the bronchoscopy had a combined sensitivity of 97%, compared to 75% for bronchoscopy alone. The genomic test's specificity was 47% in both studies. The sensitivity of the Percepta classifier alone and in combination with bronchoscopy was consistently high, regardless of nodule size and location, and cancer stage and type.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use